Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry
MR-linac Consortium
(2021) International Journal of Radiation Oncology Biology Physics, volume 111, issue 4, pp. 867 - 875
(Article)
Abstract
Purpose: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response adaptive radiation therapy paradigms. The first high-field (1.5T) MR-Linac received regulatory approval in late 2018, and little is known about
... read more
clinical use, patient tolerability of daily high-field MRI, and toxicity of treatments. Herein we report the initial experience within the MOMENTUM Study (NCT04075305), a prospective international registry of the MR-Linac Consortium. Methods and Materials: Patients were included between February 2019 and October 2020 at 7 institutions in 4 countries. We used descriptive statistics to describe the patterns of care, tolerability (the percentage of patients discontinuing their course early), and safety (grade 3-5 Common Terminology Criteria for Adverse Events v.5 acute toxicity within 3 months after the end of treatment). Results: A total 943 patients participated in the MOMENTUM Study, 702 of whom had complete baseline data at the time of this analysis. Patients were primarily male (79%) with a median age of 68 years (range, 22-93) and were treated for 39 different indications. The most frequent indications were prostate (40%), oligometastatic lymph node (17%), brain (12%), and rectal (10%) cancers. The median number of fractions was 5 (range, 1-35). Six patients discontinued MR-Linac treatments, but none due to an inability to tolerate repeated high-field MRI. Of the 415 patients with complete data on acute toxicity at 3-month follow-up, 18 (4%) patients experienced grade 3 acute toxicity related to radiation. No grade 4 or 5 acute toxicity related to radiation was observed. Conclusions: In the first 21 months of our study, patterns of care were diverse with respect to clinical utilization, body sites, and radiation prescriptions. No patient discontinued treatment due to inability to tolerate daily high-field MRI scans, and the acute radiation toxicity experience was encouraging.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Radiation, Oncology, Radiology Nuclear Medicine and imaging, Cancer Research, Journal Article
ISSN: 0360-3016
Publisher: Elsevier
Note: Funding Information: The MOMENTUM Study is financially supported by Elekta AB and through in-kind contributions from all participating institutions. Funding Information: A.C. is supported by the NIHR Manchester Biomedical Research Centre. S.H., K.H., E.H., R.H., A.K., S.L., U.O., and A.T. acknowledge the support of the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. The views expressed are those of the authors and not necessarily those of the NIHR or the Department for Health and Social Care. Funding Information: A.C. is supported by the NIHR Manchester Biomedical Research Centre. S.H. K.H. E.H. R.H. A.K. S.L. U.O. and A.T. acknowledge the support of the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. The views expressed are those of the authors and not necessarily those of the NIHR or the Department for Health and Social Care. The MOMENTUM Study is financially supported by Elekta AB and through in-kind contributions from all participating institutions. Disclosures: M.P.W.I. reports personal fees from Elekta. H.A., K.B., J.P.C., D.E., and J.G. report being employed at Elekta. A.C., B.A.E., C.F.-F., R.A.H., K.J.H., M.E.N., C.J.S., R.J.H.A.T., A.C.T., and H.M.V. report (institutional) research funding from Elekta. C.D.F. reports grants, personal fees, nonfinancial support, and other from Elekta AB; grants from the National Institutes of Health (NIH) National Institute of Dental and Craniofacial Research (NIDCR), the NIH National Institute of Biomedical Imaging and Bioengineering, the NIH National Cancer Institute (NCI), the National Science Foundation, and the NIH/NSF/NCI Interagency Institute, during the conduct of the study; and grants from NIH NCI, grants from Patient-Centered Outcomes Research Institute, grants from the NSF and NIH NIDCR, outside the submitted work. S.H. reports grants from National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, nonfinancial support from Elekta (Elekta AB, Stockholm, Sweden), personal fees and nonfinancial support from Roche, and nonfinancial support from Merck Sharp & Dohme (MSD), outside the submitted work. E.H. reports grants from Accuray Inc and Varian Medical Systems Inc, outside the submitted work. U.A.v.d.H. reports grants from Elekta and Philips Healthcare. S.L. reports grants from Elekta. K.O. was an external resource for Elekta at time of writing. A.S. was an advisor/consultant with Abbvie, Merck, Roche, Varian (medical advisory group), Elekta (gamma knife icon), BrainLAB, and VieCure (medical advisory board). A.S. was a board member for the International Stereotactic Radiosurgery Society (ISRS); had past educational seminars with Elekta AB, Accuray Inc, Varian (CNS teaching faculty), BrainLAB, and Medtronic Kyphon; reprots a research grant with Elekta AB; and reports travel accommodations/expenses from Elekta, Varian, and BrainLAB. A.S. also belongs to the Elekta MR Linac Research Consortium, Elekta Spine, Oligometastases, and Linac Based SRS Consortia. C.L.T. reports travel accommodations/expenses and honoraria for educational seminars from Elekta, outside the submitted work. W.A.H. received institutional research funding and travel support from Elekta. Publisher Copyright: © 2021
(Peer reviewed)